I n recent years, major advances have been made in the application of "omics" technologies to cardiovascular science and medicine. The year 2011 was no exception, with a number of groundbreaking studies published, ranging from the execution of ever-larger genome-wide association studies (GWAS) to the discovery of promising new diagnostic and therapeutic approaches.
The American Heart Association Functional Genomics and Translational Biology Council (www.my.americanheart.org/ fgtbcouncil) provides a forum for a multidisciplinary group of volunteers committed to making a substantial contribution to reducing the burden of heart disease and stroke through genetics, genomics, transcriptomics, proteomics, and metabolomics research and translational science. With input from the Early Career Committee of the Council on Functional Genomics and Translational Biology, we considered many articles and selected 10 outstanding ones published in 2011 that reflect these advances. In this report, we briefly summarize each.
Current therapies aimed at modulating low-density lipoprotein and high-density lipoprotein cholesterol are unable to achieve sufficient cardioprotection in all individuals. Rayner et al 1 developed a novel therapeutic approach based on the modulation of the microRNAs miR-33a and miR-33b, which downregulate expression of the cholesterol transporter ABCA1. Using a nonhuman primate model, systemic administration of an anti-miR-33a/b oligonucleotide led to increased hepatic expression of ABCA1. Additionally, expression of other miR-33 target genes was altered, with increased expression of genes involved in fatty acid oxidation and decreased expression of genes involved in fatty acid synthesis. Over 12 weeks of treatment, a sustained increase in plasma high-density lipoprotein was achieved, with evidence of larger high-density lipoprotein particle size. Concurrently, plasma levels of very-low-density lipoprotein triglycerides decreased. Although efficacy in humans remains to be established, these encouraging results from a nonhuman primate model offer an exciting example of a novel therapeutic approach with potential relevance to cardiometabolic disease in humans.
The mechanistic relationships between diet and cardiovascular disease remain incompletely understood. Wang et al 2 presented evidence of the role of intestinal microbiota in modulating the effects of dietary lipids on cardiovascular disease. Using an unbiased metabolomics approach, they found a number of metabolites in plasma to be associated with cardiovascular disease risk, with 3 of these metabolites being highly correlated with one another. Using isotopic labels in mouse models, these were identified as trimethylamine N-oxide, choline, and betaine, all metabolites of phosphatidylcholine produced by gut microflora. Trimethylamine N-oxide was found to be absent in mice lacking intestinal microbiota but could be restored by recolonization of the gut, indicating the key role of gut microflora in phosphatidylcholine metabolism. Consistent with a causal role, mice fed a high-choline diet showed increased atherosclerosis and lipid-rich macrophage foam cells compared with mice fed a low-choline diet; however, antibiotic use removed the proatherogenic effect of choline. This example of an interaction between diet and the gut microbiome in modulating disease demonstrates the complexity of nutrigenomic interactions and suggests potential therapeutic benefits of modulation of gut microflora.
In 2 independent, prospective cohorts, Wang et al 3 tested the hypothesis that targeted profiling of Ϸ60 water-soluble plasma metabolites would predict the risk of developing type 2 diabetes mellitus. Using a mass spectrometry-based metabolite profiling platform, they found 5 branched-chain and aromatic amino acids to have highly significant associations with diabetes risk. A combination of 3 of these amino acids predicted incident diabetes over a 12-year interval, with a Ͼ5-fold higher risk for individuals in the top quartile versus the bottom quartile, even after adjusting for several clinical parameters, including body mass index and dietary intake of protein, amino acids, and calories. This study illustrates how metabolomic techniques can be used to identify diseaseassociated serum markers long before the appearance of clinical disease, allowing for better risk assessment and early therapeutic interventions.
A common polymorphism in the kinesin-like protein 6 (KIF6) gene, the Trp719Arg variant, had been reported in multiple exploratory studies to be associated with both vascular risk and response to statin therapy; other studies had disputed these associations. Hopewell et al 4 sought to definitively confirm or reject the associations. Each studied Ͼ10 000 people in prospective randomized clinical trials of statin therapy and found (1) no significant difference in the event rates between KIF6 Trp719Arg carriers and noncarriers and (2) that the Trp719Arg variant is not associated with vascular risk. Notably, the 2 studies were performed with different statin drugs in different populations with different levels of vascular risk, suggesting the generalizability of the negative findings. Despite being negative, these studies are important because they have called into question the rationale for a KIF6 pharmacogenetic test to help clinicians to determine which patients should be prescribed statin therapy; at the time the studies were published, Ͼ200 000 commercial tests had reportedly been performed for this purpose. Although replication studies are now de rigueur for any genetic association study, the studies by Hopewell et al and Ridker et al show why they are mandatory when an early finding has direct clinical implications. Cammarato et al 6 demonstrated that proteomic studies based on mass spectrometry techniques are possible in the Drosophila heart, which consists of a 1-mm-long pulsatile tube formed by 52 pairs of cardiomyocytes. Analyzing just 20 g of protein from 145 Drosophila hearts, the authors identified Ͼ5100 heart-associated peptides, 50% of which were related to mitochondria and myofilament function. Overall, striking similarities to the mammalian cardiac proteome were found, with the mouse cardiac proteome serving as a benchmark. The authors highlighted many orthologs of proteins associated with cardiovascular defects in humans, suggesting that the fruitfly should be more widely used as a model to study proteins that modify cardiac function.
With 2 studies, Dietz and colleagues 7,8 followed up on their landmark observation that blocking the transforming growth factor-␤ pathway with the angiotensin type 1 (AT1) receptor blocker losartan attenuates the growth of thoracic aortic aneurysms in a mouse model of Marfan syndrome, which shed new light on the molecular mechanisms by which losartan exerts its protective effect. First, the authors demonstrated that selective AT1-blockade with losartan conferred a greater benefit compared with an angiotensin-converting enzyme inhibitor (enalapril) that blocks AT1 and AT2 receptors in a nonselective manner. Additional experiments demonstrated that the advantage of losartan is mediated in part by activation of AT2 receptor signaling. These results provide experimental evidence that selected antihypertensive drugs may be more beneficial in specific disease conditions. Second, the authors demonstrated that noncanonical transforming growth factor-␤ signaling, in particular activation of the extracellular signal-regulated kinase (ERK) 1 and 2 and Jun N-terminal kinase-1 (JNK1), plays a prominent role in aberrant growth and rupture of the aorta. These results suggest direct inhibition of these downstream effectors of transforming growth factor-␤ signaling as a promising new therapeutic strategy for patients with Marfan syndrome.
A powerful approach for the extension of GWAS utility is to examine a wider range of intermediate phenotypes. Suhre et al 9 used metabolomics to probe genome-wide associations with serum metabolites in 2820 individuals of European ancestry. They identified 37 loci with highly significant associations, many of which were between biochemically related genes and metabolites and with far greater effect sizes than typically seen for common DNA variants associated with disease phenotypes. Using the 37 identified loci, the authors examined associations of the intermediate metabolites with any plausibly related disease processes. For a number of diseases, including renal failure, diabetes mellitus, and venous thromboembolism, the authors identified credible biological relationships among the GWAS locus, the metabolite, and the disease phenotype. The use of intermediate traits, such as serum metabolites, may thus greatly increase the power of GWAS to inform disease pathophysiology.
Interpretation of the findings from GWAS often is limited by the need for follow-up studies to determine functional relevance. Gieger et al 10 provided an example of how GWAS may be extended to provide mechanistic insights into disease processes. An initial GWAS meta-analysis and second-stage replication analysis identified 68 loci for mean platelet volume and platelet count in up to 66 000 individuals of European descent. Of these loci, Ͼ20% were also significantly associated with mean platelet volume or platelet count in South Asian and Japanese populations, with Ͼ80% having the same directionality as in Europeans. Pathway and network analysis of 54 genes representing these loci identified an enrichment of genes involved in hematologic disease, cancer, and cell cycle regulation, while confirming connectivity of the novel genes with known platelet genes. These genes showed a significant increase in expression during the differentiation of hematopoietic stem cells to megakaryocytes but not to erythrocytes, demonstrating the specific relevance of these genes to platelet formation. Silencing of selected novel platelet genes in fruitfly and zebrafish models confirmed their role in erythropoiesis and thrombocyte formation. Thus, in this study, the identification of novel loci by GWAS was immediately followed up with confirmation of biological functionality, providing a template for future GWAS investigations.
